Pet Economy Stocks: Zoetis, IDEXX, and the $150 Billion Humanization Trend

The $150 Billion Economy Nobody on Wall Street Talks About

Here is a number that should stop you in your tracks. American households now spend more annually on their pets than they do on children's clothing, toys, and childcare combined. The APPA pegs total U.S. pet industry expenditures at $150.6 billion for 2024, up from $123.6 billion in 2021 and $95.7 billion in 2019. That is a 58% increase in five years. During the same period, U.S. nominal GDP grew roughly 35%. Pet spending is outpacing economic growth by a wide margin, and it has done so for three consecutive decades.

We think most investors fundamentally misunderstand this sector because they view pet companies through the lens of traditional consumer discretionary. That framework is wrong. Pet spending behaves more like a consumer staple with discretionary growth characteristics — a rare and valuable combination. The 67% household penetration rate means roughly 87 million American families own at least one pet, with multi-pet households averaging 2.3 animals. These owners do not view spending on their pets as optional. They view it as a non-negotiable part of family life.

The humanization trend is the engine. Thirty years ago, dogs ate kibble from a bag and slept in the yard. Today, 45% of dog owners share their bed with their pet, 76% buy Christmas presents for their animals, and 32% have cooked homemade meals specifically for their dogs (according to a 2024 Morgan Stanley survey). This behavioral shift has reshaped every sub-category: food has moved from commodity grain-based formulas to fresh, organic, and breed-specific nutrition. Veterinary care has evolved from basic vaccinations to MRIs, chemotherapy, and orthopedic surgery. The spending curve mirrors what happened in human food, healthcare, and wellness over the past 40 years — but compressed into half the timeline.

Where the $150 Billion Goes: Sub-Sector Economics

The pet economy is not monolithic. Each sub-sector has distinct growth profiles, margin structures, competitive dynamics, and investability. Understanding the breakdown is essential for positioning.

Two things jump out from this breakdown. First, veterinary care and animal pharma together account for nearly $57 billion and are growing at the fastest rates. Health spending on pets is following the exact trajectory of health spending on humans — the same willingness-to-pay dynamics, the same expansion of treatment options, the same shift toward preventive and chronic care management. Second, the “last discretionary cut” dynamic applies unevenly. Food and healthcare spending held firm through every recession since 1990. Supplies and discretionary services showed modest softness in 2008–2009 but recovered within two quarters. This is not a cyclical industry masquerading as secular growth. The data is unambiguous.

Zoetis: The Pfizer of Pets (But Better)

Zoetis was spun out of Pfizer in 2013 at $26 per share. It trades above $170 today. That is a 550%+ total return in twelve years, and the thesis has arguably strengthened since the IPO. Here is why we think ZTS remains the highest-quality way to play the pet economy.

The company generates approximately $9 billion in annual revenue, split roughly 75/25 between companion animal (dogs, cats, horses) and livestock. Companion animal is the growth engine — organic revenue growth of 10–12% annually driven by three forces. First, the same humanization trend that drives the broader pet economy pushes owners toward pharmaceutical solutions for conditions (arthritis, allergies, anxiety) that would have gone untreated a decade ago. Second, veterinary visit frequency is increasing as owners adopt preventive care models. Third, Zoetis's product portfolio is expanding into higher-value biologics and diagnostics.

Librela: The Blockbuster Drug Nobody Expected

Librela (bedinvetmab) is a monoclonal antibody for osteoarthritis pain in dogs — the first of its kind in veterinary medicine. The drug works by targeting nerve growth factor (NGF), the same biological pathway that human pharma companies like Pfizer and Lilly spent billions pursuing (and largely failed to commercialize in humans due to side effect profiles). In dogs, the safety and efficacy data has been exceptional: monthly injections reduce pain scores by 40–60% in clinical trials, with a side effect profile dramatically better than the NSAIDs that were previously the only option.

The market opportunity is enormous. An estimated 40% of dogs over age 8 suffer from osteoarthritis — that is roughly 25–30 million dogs in the U.S. alone. Prior to Librela, veterinarians could prescribe NSAIDs (which cause liver and kidney damage with chronic use) or gabapentin (which causes sedation). Neither was satisfactory for long-term management. Librela fills a genuine unmet medical need, and the launch trajectory reflects it. U.S. revenue exceeded $500 million in its first full year on the market, making it one of the fastest-growing animal health products ever launched. Management has guided to $1–2 billion in peak global revenue, and based on the penetration curves we're seeing, that looks conservative. A feline version (Solensia, targeting the same NGF pathway) adds another $300–500 million in peak potential.

The No-Generic-Cliff Advantage

This is the part that human pharma investors envy. The animal health industry has no Paragraph IV abbreviated pathway for generic drugs. There is no “Hatch-Waxman Act for pets.” While generic competition does eventually emerge for some small-molecule veterinary drugs, the timeline is measured in decades rather than years, and biologics like Librela face no meaningful biosimilar threat for the foreseeable future. Zoetis's parasiticide franchise (Simparica Trio, which generated $2.8 billion in 2024 revenue) has been on the market for years and still commands premium pricing with minimal share erosion. Compare that to a human pharma company watching 80% of a drug's revenue evaporate within 18 months of patent expiry. The durability of animal health revenue streams justifies a structural premium to human pharma multiples. For a framework on evaluating these kinds of competitive advantages, see our guide on analyzing competitive moats.

IDEXX Laboratories: The Monopoly Hiding in Plain Sight

If Zoetis is the Pfizer of pets, IDEXX is the LabCorp, Quest Diagnostics, and Abbott Laboratories rolled into one. The company commands approximately 80% of the U.S. veterinary reference laboratory market and roughly 60% of the in-clinic diagnostics equipment installed base. Those numbers are not typos. IDEXX has one of the most dominant market positions in all of healthcare, human or animal.

The business model is a textbook razor-and-blade. IDEXX places Catalyst chemistry analyzers, ProCyte hematology systems, and SediVue urine analyzers in veterinary clinics at subsidized or lease-based pricing. Once installed, these instruments generate high-margin consumable revenue every time a test is run. The average veterinary practice running IDEXX equipment generates $45,000–$65,000 in annual diagnostic consumable revenue for the company. With over 40,000 practices in the U.S. running IDEXX instruments, the recurring revenue base exceeds $2.5 billion domestically before accounting for reference lab volumes.

Why Vets Cannot Switch Away from IDEXX

The switching costs in veterinary diagnostics are staggering. IDEXX's VetConnect PLUS cloud platform stores years of patient diagnostic history for every animal that has been tested at a practice. If a veterinarian switches to a competitor, they lose the ability to compare current results against historical baselines — a capability that is medically essential for managing chronic conditions like kidney disease, diabetes, and thyroid disorders in aging pets. Add in staff retraining costs, equipment replacement logistics, and the risk of laboratory result discrepancies during transition, and you understand why contract renewal rates exceed 95%. This is not a 75% retention business where you worry about churn. It is a 95%+ retention business where the installed base grows 3–5% annually and same-store revenue grows another 5–8% on top of that from increased test utilization.

The growth driver going forward is diagnostic frequency. The average dog visit in the U.S. includes 1.8 diagnostic tests today versus 1.2 a decade ago. IDEXX's data shows that practices running comprehensive diagnostic panels have 40% higher per-visit revenue and 25% better patient outcomes (measured by early disease detection rates). As the standard of veterinary care continues rising — driven by both pet owner expectations and veterinarian training — diagnostic utilization per visit will continue expanding. IDEXX management has guided for 8–10% organic revenue growth through 2028, which we think is achievable given these structural tailwinds.

Chewy: The Anti-Amazon Playbook in Pet E-Commerce

Chewy is the company that should not exist. Conventional wisdom says Amazon crushes all e-commerce verticals eventually. Chewy has not only survived but thrived, growing net revenue from $3.5 billion in 2018 to over $11.5 billion in 2025. The stock has been volatile — it went public at $22 in 2019, peaked above $120 in 2021, crashed to $15 in 2023, and has recovered to the $35–40 range as profitability inflected. The question for investors is whether Chewy's unit economics justify a long-term holding or whether this is a transient competitive advantage destined to erode.

Autoship: 78% of Sales on Autopilot

The Autoship program is the moat. Over 78% of Chewy's net sales come through Autoship subscriptions, where customers schedule recurring deliveries of food, litter, medications, and supplements. This is not a “subscribe and save 5%” gimmick. Autoship customers exhibit fundamentally different economics: they have 2.5x higher lifetime value, 4x lower churn rates, and spend progressively more over time as they add products to their recurring orders. Net revenue per active customer has grown from $344 in 2018 to over $580 in 2025, reflecting both premiumization and basket expansion within the Autoship framework.

The behavioral lock-in is real. Once a pet owner has configured their Autoship schedule — 30-pound bag of Orijen every 6 weeks, flea medication every 3 months, dental chews every month — the activation energy required to switch to Amazon or Walmart.com is disproportionately high relative to any savings. You have to recreate the entire schedule, re-enter payment information, and risk disrupting a cadence that keeps your pet fed and medicated. It is the same subscription inertia that powers Netflix and Spotify, but applied to a category where disruption (running out of dog food) has real consequences.

The Profitability Inflection

The knock on Chewy for years was profitability. That narrative has shifted. Chewy generated positive adjusted EBITDA margins of 4.5% in fiscal 2025, up from breakeven in 2023, driven by higher-margin product mix (pharmacy, healthcare, premium brands), advertising revenue from its retail media network, and fulfillment center automation reducing per-order costs by 12%. The company produced its first full year of positive free cash flow in 2025. Chewy Health — encompassing pharmacy, telehealth, and pet insurance — is the highest-margin vertical, growing at 30%+ annually and representing roughly 15% of total revenue. If Chewy can push EBITDA margins to 6–8% over the next three years (management's target), the stock at 1.2x EV/Revenue and 20x forward EBITDA looks reasonably priced for a subscription-dominant e-commerce business growing mid-single-digits.

Freshpet: The Lululemon of Pet Food

Freshpet is the highest-growth and highest-risk name on this list. The company makes refrigerated, fresh pet food — think deli-counter-quality chicken and vegetable rolls, bags, and meal formats that sit in branded fridges inside grocery stores, pet specialty retailers, and mass merchants. Revenue has compounded at 28% annually over the past five years, reaching approximately $1 billion in 2025. The total addressable market for fresh and refrigerated pet food is estimated at $15–20 billion in North America alone, implying Freshpet has penetrated roughly 5–7% of its long-term opportunity.

The analogy to human food premiumization is direct. Twenty years ago, nobody paid $8 for a bottle of cold-pressed juice or $12 for a grain bowl. Today, the premium natural food segment is a $200 billion market in the U.S. Pet food is following the same arc with a lag of approximately 10–15 years. Freshpet's value proposition — real, recognizable ingredients, refrigerated for freshness, portioned for convenience — targets the same consumer psychology that drives Whole Foods and Sweetgreen. The average Freshpet customer spends $80–100 per month on fresh pet food, roughly 2–3x what they would spend on premium dry kibble. They do not trade down. Freshpet's household retention rate exceeds 50% after the first year, and retained households increase spending by 15–20% in year two.

The risk is execution. Freshpet has historically struggled with manufacturing capacity constraints, quality control incidents, and margin volatility driven by ingredient cost inflation. The company's Kitchens South facility in Ennis, Texas (a $500 million+ investment) is ramping to address the capacity bottleneck and should support revenue through $2 billion. But the stock trades at 60x+ forward earnings (when GAAP profitable) or roughly 5x EV/Revenue, pricing in flawless execution and sustained 20%+ growth. Any hiccup in same-store growth, fridge placement expansion, or margin progression will be punished severely at this valuation.

The Veterinary Shortage: Structural Constraint, Structural Opportunity

There are approximately 120,000 practicing veterinarians in the United States. The Bureau of Labor Statistics projects demand for 14,000 additional vets by 2032, but veterinary schools graduate only about 4,500 new DVMs annually, and retirement rates are accelerating as the Boomer generation of veterinarians exits the workforce. The math does not work. The shortage is already acute: average wait times for veterinary appointments have increased from 2.1 days in 2019 to 4.8 days in 2025, and emergency veterinary clinics report regular 6–12 hour waits.

For investors, the vet shortage is both a risk and an opportunity. It constrains total visit volumes, which is a headwind for IDEXX's same-store diagnostic growth. But it creates enormous pricing power: veterinary service pricing has increased 8–12% annually for three consecutive years, far exceeding general inflation. Clinics can raise prices because demand exceeds supply, and pet owners — emotionally bonded to their animals and lacking alternatives — absorb the increases. This pricing dynamic benefits Zoetis directly (higher-priced vet visits create a larger basket for pharmaceutical products), benefits IDEXX indirectly (vets running more diagnostics per visit to maximize revenue per appointment), and benefits the entire pet healthcare ecosystem.

Corporate consolidation is the other consequence. Mars Veterinary Health (Banfield, BluePearl, VCA), JAB Holdings (NVA), and private equity-backed platforms like Thrive Pet Healthcare are aggressively acquiring independent practices, now controlling approximately 30–35% of the U.S. veterinary market, up from 15% a decade ago. Corporatization improves operating efficiency (centralized procurement, standardized protocols, shared services) and increases adoption of advanced diagnostics and pharmaceuticals — all of which benefit Zoetis and IDEXX as suppliers to these consolidated networks.

Pet Economy Stocks: Head-to-Head Comparison

The Bear Case: What Could Go Wrong

Pet Ownership Is Plateauing

The pandemic drove a surge in pet adoptions that is now normalizing. U.S. pet ownership peaked at approximately 70% of households in 2022 and has drifted back to 66–67%. Shelter intake data from the ASPCA shows surrenders increasing 15% year-over-year in 2024 and 2025 as pandemic-era owners grapple with the long-term costs of pet ownership. For younger demographics, the math is unfavorable: a dog costs $2,500–4,000 annually to maintain, apartment pet deposits average $200–500, and pet-friendly rentals carry $50–100/month premiums. With 62% of Gen Z renters and housing affordability at a 40-year low, the next generation of potential pet owners faces structural barriers that did not exist for Boomers and Gen X.

Valuations Leave No Room for Error

The pet economy stocks trade at a collective premium that prices in near-perfect execution. Zoetis at 35x, IDEXX at 45x, and Freshpet at 60x do not offer margin of safety if growth decelerates by even 2–3 percentage points. In 2022, when IDEXX reported a quarter of slower-than-expected vet visit growth, the stock dropped 20% in a single session. Freshpet fell 40% in 2022 on manufacturing quality concerns. These are high-quality businesses, but the valuations mean the risk/reward is asymmetric on the downside for incremental buyers. A 5-turn multiple compression on IDEXX (from 45x to 40x) erases roughly $5 billion in market cap — the equivalent of three years of earnings growth.

Competition Is Intensifying

Zoetis faces emerging competition from Elanco (ELAN) in parasiticides and from smaller biotech firms developing competing monoclonal antibodies. IDEXX's diagnostics dominance is being tested by Antech (Mars Veterinary Health) and Heska (now part of Mars), which are investing aggressively in reference lab capacity and in-clinic instruments. Chewy's e-commerce position is under constant pressure from Amazon's expanding pet category, Walmart's fulfillment investments, and Petco/PetSmart omnichannel strategies. None of these competitive threats are existential in the near term, but they constrain pricing power and market share gains at the margin. The pet economy is large enough for multiple winners, but the question is whether current valuations properly discount the intensifying competitive environment.

Portfolio Construction: How We Would Play This

Our preferred approach is a barbell. Allocate the core position (60–70% of pet economy exposure) to Zoetis and IDEXX — the highest-quality compounders with the widest moats and most predictable growth. These are businesses you can hold for a decade. The growth characteristics are structural, the competitive positions are nearly unassailable, and the only real risk is overpaying. We would initiate or add to positions on 10–15% pullbacks from all-time highs, which historically occur once or twice per year on quarterly earnings volatility.

The satellite allocation (30–40%) goes to Chewy and Freshpet, which offer higher upside but require active management. Chewy's valuation is most attractive in the group today — it trades at a significant discount to its subscription peers on EV/Revenue and has a clear path to margin expansion. Freshpet is the highest-beta name: spectacular in a bull market, painful in a correction. We would size Freshpet at no more than 2–3% of a diversified portfolio and treat it as a call option on the fresh pet food category reaching $10B+ in the next decade.

Trupanion (TRUP) is the one we are watching but not yet buying. Pet insurance penetration in the U.S. sits at roughly 4%, compared to 25% in the UK and 40% in Sweden. If U.S. penetration reaches even 15% over the next decade, Trupanion's direct-to-consumer model and veterinary practice integrations position it to capture disproportionate share. But the company has yet to demonstrate consistent profitability, combined ratios remain above 100%, and the stock trades at a valuation that assumes penetration rates that may take longer than bulls expect. For context on evaluating growth stocks with unproven unit economics, see our guide on analyzing unit economics in growth stocks.

Frequently Asked Questions